Clinical Trial Update: A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating oral ciclopirox (ATL-001) for CEP. It aims to improve photosensitivity and skin lesions in adults and is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Erythropoietic Porphyria

Drugs mentioned

• ATL-001 (Ciclopirox oral solution) (Ciclopirox)

Snippet

Sponsor: Atlas Molecular Pharma | Conditions: Congenital Erythropoietic Porphyria (CEP) | Phase 1, Phase 2 | Status: RECRUITING